Lithium In Vitro Enhances Interleukin-2 Production by T Cells from Patients with Systemic Lupus Erythematosus

References

• Tsokos G. C., Balow J. E. Cellular immune responses in systemic lupus erythematosus. Prog. Allergy 1984; 35: 93
   PubMedGoogle Scholar
• Chorazzi N. An overview of cellular immune function in systemic lupus erythematosus. Systemic lupus erythematosus, R. G. Lahita, New York 1987; 23–63
   Google Scholar
• Alcocer-Varela J., Alarcon-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J. Clin Invest 1982; 69: 1388
   PubMed Web of Science ®Google Scholar
• Linker-Israeli M., Bakke A. C., Kitriodou R. C., Gendler S., Gillis S., Horwitz D. A. Defective production of inter-leukin-1 and interleukin-2 in patients with systemic lupus erythematosus. J. Immunol. 1983; 130: 2651
   PubMed Web of Science ®Google Scholar
• Linker-Israeli M., Bakke A. C., Quismorio F. P., Jr, Horwitz D. A. Correction of interleukin-2 production in patients with systemic lupus erythematosus by removal of spontaneously activated suppressor cells. J. Clin. Invest. 1985; 75: 762
   PubMed Web of Science ®Google Scholar
• Miyasaka N., Nakamura T., Russell I. J., Talal N. Interleukin-2 deficiences in rhematoid arthritis and systemic lupus erythematosus. Clin. Immunol. Immunopathol. 1984; 31: 109
   PubMedGoogle Scholar
• De Faucal P., Godard A., Peyrat M. A., Moreau J. F., Soulilou J. P. Impaired IL-2 production by lymphocytes of patients with systemic lupus erythematosus. Ann. Immunol., (Paris) 1984; 135D: 161
   PubMedGoogle Scholar
• Murakawa Y., Takeda S., Ueda Y., Suzuki N., Hashino T., Sakane T. Characterization of T lymphocyte sub-populations responsible for deficient interleukin-1 activity in patients with systemic lupus erythematosus. J. Immunol. 1985; 134: 187
   PubMed Web of Science ®Google Scholar
• Murakawa Y., Sakane T. Deficient phytohe-magglutinin-induced interleukin-2 activity in patients with inactive systemic lupus erythematosus is correctable by the addition of phorbol myristate acetate. Arthritis Rheum. 1988; 31: 826
   PubMedGoogle Scholar
• Gaspar M. L., Alvarez-Mon M., Gutierrez G. The B-cell activation pathway in human sytemic lupus erythematosus: imbalances in vitro production of lymphokines and association with serum analytical findings. J. Clin. Immunol. 1988; 8: 266
   Google Scholar
• Sierakowski S. J., Kucharz E. J., Lightfoot R. W., Jr, Goodwin J. S. Impaired T-cell activation in patients with systemic lupus erythematosus. J. Clin. Immunol. 1989; 9: 469
   PubMed Web of Science ®Google Scholar
• Dauphinee M. J., Kipper S. B., Raskos K, Wofsy D., Tatal N. Androgen treatment of autoimmune NZB/W mice enhances TL-2 production. Arthritis Rheum. 1981; 24(Suppl.)564A
   Google Scholar
• Wofsy D., Murphy E. D., Roths J. B., Dauphinee M. J., Kipper S. B., Talal N. Deficient interleukin-2 activity in MRL/Mp and C57/6J mice bearing the lpr gene. J. Exp. Med. 1981; 154: 1671
   PubMed Web of Science ®Google Scholar
• Dauphinee M. J., Kipper S. B., Wofsy D., Talal N. Interleukin-2 deficiency is a common feature of autoimmune mice. J. Immunol. 1981; 127: 2483
   PubMed Web of Science ®Google Scholar
• Altman A., Theofilopoulos A. N., Weiner R, Katz D. H., Dixon F. J. Analysis of T cell function in autoimmune murine strain. Defects in production and responsiveness to interleukin-2. J. Exp. Med. 1981; 154: 79
   Google Scholar
• Robb R. J. Interleukin-2., the molecule and its function. Immunol. Today 1984; 5: 203
   PubMedGoogle Scholar
• Kucharz E. J. Rola interleukiny-2 w zaburzonej regulacji immunologicznej w ukladowym toczniu trzewnym. Pol. Tyg. Lek. 1988; 43: 619
   Google Scholar
• Kucharz E. J. Impaired interleukin-2 production as one mechanisms of disturbed immune regulation in systemic lupus erythematosus. Ann. Acad. Med. Siles. 1991; 24: 211
   Google Scholar
• Alcocer-Varela J., Laffon A., Alarcon-Segovia D. Defective monocyte production of, and T lymphocyte response to, interleukin-1 in the peripheral blood of patients with systemic lupus erythematosus. Clin Exp. Immunol. 1983; 54: 125
   Google Scholar
• Whicher J. T., Gilbert A. M., Westacott C., Hutton C., Dieppe P. A. Defective production of leukocytic endogenous mediator (interleukin-1) by peripheral blood leukocytes of patients with systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis and mixed connective disease. Clin. Exp. Immunol. 1986; 65: 80
   Google Scholar
• Sierakowski S. J., Kucharz E. J., Lightfoot R. W., Jr, Goodwin J. S. Interleukin-1 production by monocytes from patients with systemic lupus erythematosus. Clin. Rheumatol. 1987; 6: 403
   Google Scholar
• Kucharz E. J., Sierakowski S. J., Goodwin J. S. Decreased activity of interleukin-1 inhibitor in plasma of patients with systemic lupus erythematosus. Clin. Rheumatol. 1988; 7: 87
   Google Scholar
• Djeu J. T., Kasahara T., Balow J. E., Tsokos G. C. Decreased interleukin-2 inhibitor in sera of patients with autoimmune disorders. Clin. Exp. Immunol. 1986; 65: 279
   PubMed Web of Science ®Google Scholar
• Kucharz E. J., Goodwin J. S. Serum inhibitors of interleukin-2. Life Sci. 1988; 42: 1485
   PubMed Web of Science ®Google Scholar
• Kucharz E. J., Sierakowski S. J., Staite N. D., Goodwin J. S. Mechanism of lithium-induced augmentation of T-cell proliferation. Int. J. Immunopharmacol. 1988; 10: 253
   Google Scholar
• Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25: 1271
   PubMed Web of Science ®Google Scholar
• Sherman W. R., Gish B. G., Honcar M. P., Munsell L. Y. Effects of lithium on phosphoinositide metabolism in vivo. Fedn. Proa 1986; 45: 2639
   PubMedGoogle Scholar
• Thornhill D. P. Serum levels and pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients during chronic dosage. Int. J. Clin. Pharmac. Ther. Toxic 1986; 24: 257
   Google Scholar